PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma

被引：10
|
作者：
Mittlmeier, L. M. [1 ,2 ]
Unterrainer, M. [2 ,3 ]
Todica, A. [2 ]
Cyran, C. C. [3 ]
Rodler, S. [1 ]
Bartenstein, P. [2 ]
Stief, C. G. [1 ]
Ilhan, H. [2 ]
Staehler, M. [1 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Urol, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Nucl Med, Munich, Germany
[3] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiol, Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / 09期
关键词：
D O I：
10.1007/s00259-019-04636-6
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
[No abstract available]
引用
收藏
页码：2216 / 2217
页数：2
相关论文
共 50 条
  • [31] Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor
    Mizuno, Ryuichi
    Miyajima, Akira
    Oya, Mototsugu
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (07) : 740 - 740
  • [32] PSMA PET-CT in assessment of advanced renal cell carcinoma - an effective modality in discerning metastatic disease
    Ong, Katherine
    Teichmann, Dominic
    Hayne, Dickon
    BJU INTERNATIONAL, 2022, 129 : 153 - 154
  • [33] A phase II study of S-1 for the treatment of cytokine and/or tyrosine-kinase inhibitor (TKI) refractory metastatic renal cell carcinoma: Updated results.
    Tomita, Yoshihiko
    Shinohara, Nobuo
    Mizokami, Atsushi
    Fujisawa, Masato
    Hashine, Katsuyoshi
    Nishikido, Masaharu
    Nakagawa, Masayuki
    Akaza, Hideyuki
    Tsukamoto, Taiji
    Naito, Seiji
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [34] Initial experience using PSMA PET/CT in metastatic renal cell carcinoma: A multicentre retrospective cohort study
    Kwok, Michael
    Tariq, Arsalan
    Pearce, Adam
    Rhee, Handoo
    Thomas, Paul
    Pattison, David A.
    Kyle, Samuel
    Navaratnam, Anojan
    Dunglison, Nigel
    Esler, Rachel
    Yaxley, John W.
    Roberts, Matthew J.
    BJU INTERNATIONAL, 2022, 129 : 30 - 30
  • [35] Cytoreductive Nephrectomy in Metastatic Clear-Cell Renal Cell Carcinoma: Perspectives in the Tyrosine Kinase Inhibitor Era
    Biswas, Swethajit
    Kelly, John
    Eisen, Tim
    ONCOLOGIST, 2009, 14 (01): : 52 - 59
  • [36] The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy
    Noboru Nakaigawa
    Keiichi Kondo
    Daiki Ueno
    Kazuhiro Namura
    Kazuhide Makiyama
    Kazuki Kobayashi
    Koichi Shioi
    Ichiro Ikeda
    Takeshi Kishida
    Tomohiro Kaneta
    Ryogo Minamimoto
    Ukihide Tateishi
    Tomio Inoue
    Masahiro Yao
    BMC Cancer, 17
  • [37] The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy
    Nakaigawa, Noboru
    Kondo, Keiichi
    Ueno, Daiki
    Namura, Kazuhiro
    Makiyama, Kazuhide
    Kobayashi, Kazuki
    Shioi, Koichi
    Ikeda, Ichiro
    Kishida, Takeshi
    Kaneta, Tomohiro
    Minamimoto, Ryogo
    Tateishi, Ukihide
    Inoue, Tomio
    Yao, Masahiro
    BMC CANCER, 2017, 17
  • [38] Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era
    Tsao, Che-Kai
    Small, Alexander C.
    Kates, Max
    Gartrell, Benjamin Adam
    Wisnivesky, Juan P.
    Sonpavde, Guru
    Palese, Michael
    Hall, Simon
    Oh, William K.
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma
    Koo, Dong-Hoe
    Park, Inkeun
    Ahn, Jin-Hee
    Lee, Dae-Ho
    You, Dalsan
    Jeong, In-Gab
    Song, Cheryn
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    Lee, Jae-Lyun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (02) : 339 - 347
  • [40] Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
    Tomas Buchler
    Alexandr Poprach
    Targeted Oncology, 2024, 19 : 175 - 180
12345